- Home
- / Cingulate
Cingulate
Stock Price
$4.4
2024-10-29
Market Capitalization
$13.2 M
2024-10-28
Cingulate Summary
Company Summary
- Overview
- Cingulate is a clinical-stage biopharmaceutical company that develops medications for patients with attention deficit hyperactivity disorder (ADHD) and anxiety. The company utilizes using its proprietary precision timed release (PTR) drug delivery platform technology. Its product candidates include CTx-1301 and CTx-1302 for the treatment of ADHD and CTx-2103 for the treatment of anxiety.
- Type
- Public
- Status
- Active
- Founded
- 2021
- HQ
- Kansas City, KS, US | view all locations
- Website
- https://www.cingulate.com/
- Cybersecurity rating
Table of Contents
Key People
Raul R. Silva, Chief Science Officer
Laurie Myers, Chief Operating Officer
Matthew Brams, Chief Medical Officer
LocationsView all
2 locations detected
Kansas City, KS HQ
United States
1901 W 47th Place
Morristown, NJ
United States
6 South Street, Suite 203
Cingulate Financials
Summary Financials
- Net income (Q1, 2026)
- ($9.3M)
- Cash (Q1, 2026)
- $25.9M
- EBIT (Q1, 2026)
- ($7.9M)
- Enterprise value
- ($5.3M)